Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    systematic_literature_reviews_whitepaper
    Demystifying the SLR: “S” stands for systematic

    A structured approach to evidence-based decision-making.

    biosimilars and oncology
    The future of oncology biosimilars

    Considerations for development through 2040.

    icons connected through network_artificail_intelligence
    Decoding AI in software as a medical device (SaMD)

    Regulatory insights and market strategies.

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Enhancing clinical trials in obesity by integrating COAs and DHTs

    7 October 2025. Register now.

    whitepaper CNS
    Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

    22 October 2025. Register now.

  • About ICON
    About ICON
    Company history ICON at a glance Healthcare Intelligence ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Medical analytics presentation preview
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. Insights
  3. Blog page
  4. How to ensure your trial data and patients remain safe during COVID-19

How to ensure your trial data and patients remain safe during COVID-19

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

  • 19 April 2024

The COVID-19 pandemic has presented an array of cybersecurity challenges. With no slowing down of the virus’s spread, hackers and other cyber criminals are continuing to seize opportunities to take advantage of vulnerable networks.

Companies are facing technology risks as more people work remotely, including unmanaged devices and insecure IT access, which is leading to increased phishing scams. For example, as more people work remotely and use telemedicine services, more cybersecurity issues are surfacing, such as incidents of videoconferencing accounts being sold on the dark web. Security firm, Zscaler, claims to have experienced a stunning 30,000% increase since January in detected phishing, malicious websites and malware designed to capitalize on the COVID-19 crisis. Similarly, according to the C5 Alliance, cyber-attacks have increased by 150 percent in the healthcare sector over the past two months, as criminals seek to take advantage of system vulnerabilities during the pandemic.

Also, hospital systems and clinical trial sites are particularly vulnerable to ransomware as their services are more vital now.  As noted by an alert issued by Interpol in early April, cybercriminals are using ransomware to target healthcare organisations already overwhelmed by COVID-19, suggesting an increased likelihood to pay hefty sums of money. This surge in ransomware incidents include an Illinois Public Health District website, a Czech hospital system, and a UK medical testing facility.

Opportunistic cyber criminals can use the current pandemic to steal intellectual property and patient information. Further, medical devices and other connected devices and networks, which make up the internet of medical things (IoMT), can easily be targeted as users frequently shift from secure healthcare networks to unsecured public Wi-Fi networks. Cyber-attack schemes include hacking medical devices either to control them or to be used as a backdoor into a hospital’s IT network. 

To date, there is a 26 percent chance that 14 percent of patient monitoring tools will get attacked, according to research conducted by Atlas VPN. The research also reported that 27 percent of medical devices are still running Windows XP or decommissioned versions of Linux OS, leading these devices to increased vulnerabilities and cyber threats. 

As no standard operating system for medical products exists, most medical devices use easily compromised off-the-shelf software. In addition, if a device’s security software is not automatically updated, it can leave further vulnerabilities. 

During this time, digital health technologies have the opportunity to mitigate challenges and relieve burdens to patients and healthcare systems. Yet, it is important to understand potential cyber threats and how to implement proper measures to ensure the safety of patients and trial data. Learning how to better design and include security in devices and systems at the beginning of development will best protect users, as it is more difficult to add security features after creation. As healthcare systems, device manufacturers and software developers rapidly make changes to thwart cyber criminals, we advise to exercise extreme vigilance, as successful attacks will continue to exacerbate current and future challenges. 

Implementing data security best practices

Adhering to best practices regarding patient data privacy remains important during times of crisis as more sponsors, sites and patients increasingly rely on remote communications. Protecting new and existing sources of patient data starts with making sure data is handled securely and that patient data is protected, and in line with the EU’s General Data Protection Regulation.

Users and site administrators of applications and softwares should adhere to best practices for password security, such as ensuring strong passwords and multi-factor authentication. Software and hardware should have the latest security patches, and anti-malware software should be deployed. Networks should be continuously monitored — in addition to the networks where IoMT devices are connected — for suspicious behaviour. Further, data backup plans should be established in separate and secure locations.

Harnessing new technologies, such as blockchain, can improve the privacy of sharing data across large networks of users and can keep track of data transactions through a tamper-proof chain of custody of all medical devices. 

Developing a cybersecurity plan that addresses IoMT

Countering cyber-attacks starts by incorporating safety measures from the beginning of a device’s or app’s development and creating a device cybersecurity strategy. The first step is to develop a risk-based cybersecurity plan that addresses overall vulnerability issues with regard to safety, security, privacy, automation, software and design. 

Second, medical device manufacturers should make provisions to ensure that device design is simple and easy to update, and adheres to regulatory guidelines. Also, manufacturers should plan vulnerability management processes, ensuring that fixes can be rapidly developed and deployed. At the same time, processes and protocols to handle security breaches will need to be defined. 

In addition, medical device developers will need to include specific security features such as:

  • Structured processes for limiting access to devices
  • Proven secure design and communications protocols
  • Secure standard operating procedures
  • Periodic software tests and security updates

Moreover, device assessment automation tools should be employed to aid IT professionals in determining where cybersecurity attacks originate. Advantages to automation software include installation of security patches, cloud-based security solutions and traffic analytics tools. In addition, blockchain, AI and machine learning can be leveraged to identify and respond to cyber-attacks in real time, and used to apply adaptive security controls to medical devices, such as additional authentication. 

Collaborating is key

Finally, seeking the advice of IT and medical device experts is crucial since they can provide information about any known computer operating system legacy vulnerabilities. The integration of IoMT and expanded use of networks has brought new opportunities for cyber criminals. Investing in and integrating cybersecurity measures in devices, apps, software and networks can go a long way to preventing future vulnerabilities. 

To learn more about how ICON experts can help you ensure your clinical trial data and patients remain safe, please contact us. 
 

COVID-19 clinical operations

Keeping your clinical trial on track in an evolving environment. 

Healthcare system preparedness for respiratory pandemics

Adapting operations to changing conditions

ICON has adapted its services to support sponsors during this time; offering remote monitoring where on-site visits were not permitted, providing additional support to get IMP to patients and pre-recording investigator meetings because of travel restrictions.

Cardiovascular risk factors during viral outbreaks

Treatment and vaccine trials for COVID-19

ICON is proud to be supporting clients and government organisations in the search for a treatment or vaccine for COVID-19. Download our whitepaper on Pandemic respiratory vaccine clinical trials.

In this section
In this section
  • Digital Disruption
    • Clinical strategies to optimise SaMD for treating mental health
    • Digital Disruption: Surveying the industry's evolving landscape
    • AI and clinical trials
      • Impact of AI on Outcomes Based Contracting
      • Using AI for site ID and selection
      • Applying AI to manage the risks and costs of postmarketing requirements
      • Integrating AI into Clinical Research: How AI is Enhancing Clinical Development
    • Clinical trial data anonymisation and data sharing
    • Clinical Trial Tokenisation
    • Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
    • Digital disruption in biopharma
    • Disruptive Innovation
    • mHealth wearables
      • Bring Your Own Device
      • Cybersecurity
        • Addressing cybersecurity for your medical device
      • Digital Endpoints
      • Transforming Medical Device Development with mHealth
    • Personalising Digital Health
    • Real World Data
      • Harnessing technology to maximise Real World Evidence value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
    • The triad of trust: Navigating real-world healthcare data integration
    • Decoding AI in software as a medical device (SaMD)
    • Software as a medical device (SaMD)
  • Patient Centricity
    • Agile Clinical Monitoring
    • Capturing the voice of the patient in clinical trials
    • Charting the Managed Access Program Landscape
    • Developing Nurse-Centric Medical Communications
    • Representation and inclusion in clinical trials
      • Diversity and inclusion in clinical trials whitepaper
    • Exploring the patient perspective from different angles
    • Patient safety and pharmacovigilance
      • A guide to safety data migrations
      • Taking safety reporting to the next level with automation
      • Outsourced Pharmacovigilance Affiliate Solution
      • The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
      • Sponsor and CRO pharmacovigilance and safety alliances
      • Understanding the Periodic Benefit-Risk Evaluation Report
    • Patient voice survey
    • Patient Voice Survey - Decentralised and Hybrid Trials
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
    • Using longitudinal qualitative research to capture the patient voice
    • Prioritising patient-centred research for regulatory approval
  • Regulatory Intelligence
    • Accelerating access
    • Navigating the regulatory landscape in the US and Japan:
    • An innovative approach to rare disease clinical development
    • EU Clinical Trials Regulation
      • EMA guideline on computerised systems and electronic data in clinical trials
      • EU CTR Whitepaper
    • Using innovative tools and lean writing processes to accelerate regulatory document writing
    • Current overview of data sharing within clinical trial transparency
    • Global Agency Meetings: A collaborative approach to drug development
    • Keeping the end in mind: key considerations for creating plain language summaries
    • Navigating orphan drug development from early phase to marketing authorisation
    • Procedural and regulatory know-how for China biotechs in the EU
    • RACE for Children Act
    • Early engagement and regulatory considerations for biotech
    • Regulatory Intelligence Newsletter
    • Requirements & strategy considerations within clinical trial transparency
    • Spotlight on regulatory reforms in China
    • Demystifying EU CTR, MDR and IVDR
    • Transfer of marketing authorisation
    • Exploring FDA guidance for modern Data Monitoring Committees
    • Streamlining dossier preparation
  • Therapeutics insights
    • Endocrine and Metabolic Disorders
    • Cardiovascular
      • Mitigating the impact of COVID-19 on cardiovascular trials
    • Cell and Gene Therapies
      • Approaching the CAR T-cell therapy horizon
      • Cell and Gene ebook
      • Long-term follow-up studies of cell and gene therapies
      • Mainstreaming Cell & Gene Therapies
    • Central Nervous System
      • A mind for digital therapeutics
      • Challenges and opportunities in traumatic brain injury clinical trials
      • Challenges and opportunities in Parkinson’s Disease clinical trials
      • Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
      • Key Considerations in Chronic Pain Clinical Trials
      • ICON survey report: CNS therapeutic development
    • Glycomics
    • Infectious Diseases
      • Antimicrobial Resistance
      • Considerations for strengthening vaccine development
      • COVID-19 vaccine trials
      • COVID-19 vaccines: Post-authorisation safety surveillance
      • HIV
      • The value of dynamic transmission models
    • NASH
      • The voice of NASH investigators
    • Obesity
      • Addressing obesity's impact across the disease spectrum
      • Trends and challenges in obesity research and clinical trials
      • Obesity and beyond: embracing multi-indication potential during clinical development
      • Survey report: How today’s obesity developers are navigating a multi-indication landscape
    • Oncology
      • ICON survey report: Innovation in Oncology
      • De-risking clinical development of precision medicines in oncology
      • Advances in imaging biomarkers: Estimating drug efficacy with tumour growth rate modelling
      • The future of oncology biosimilars
    • Paediatrics
      • Paediatric Risk Assessment Map
    • Respiratory
    • Rare and orphan diseases
      • Advanced therapies for rare diseases
      • Cross-border enrollment of rare disease patients
      • Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
      • Diversity, equity and inclusion in rare disease clinical trials
      • Identify and mitigate risks to rare disease clinical programmes
      • Leveraging historical data for use in rare disease trials
      • Natural history studies to improve drug development in rare diseases
      • Patient Centricity in Orphan Drug Development
      • The key to remarkable rare disease registries
      • Therapeutic spotlight: Precision medicine considerations in rare diseases
  • Transforming Trials
    • Accelerating biotech innovation from discovery to commercialisation
    • Demystifying the Systematic Literature Reviews
    • Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
    • Linguistic validation of Clinical Outcomes Assessments
    • Optimising biotech funding
    • Adaptive clinical trials
      • Adaptive Design: The Faster Path to Market
    • Best practices to increase engagement with medical and scientific poster content
    • Decentralised clinical trials
      • Biopharma perspective: the promise of decentralised models and diversity in clinical trials
      • Decentralised and Hybrid clinical trials
      • Practical considerations in transitioning to hybrid or decentralised clinical trials
      • Navigating the regulatory labyrinth of technology in decentralised clinical trials
    • eCOA implementation
    • Blended solutions insights
      • Clinical trials in Japan: An enterprise growth and management strategy
      • How investments in supply of CRAs is better than competing with the demand for CRAs
      • The evolution of FSP: not just for large pharma
      • Embracing a blended operating model
      • Observations in outsourcing: Survey results show a blended future
    • Implications of COVID-19 on statistical design and analyses of clinical studies
    • Improving pharma R&D efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Innovation in Clinical Trial Methodologies
    • Partnership insights
      • Exploring partnership culture and its impact on outsourcing and operational strategy
    • Risk Based Quality Management
    • Transforming the R&D Model to Sustain Growth
    • Behind Biotech: Stories of science and resilience
  • Value Based Healthcare
    • Strategies for commercialising oncology treatments for young adults
    • US payers and PROs
    • Accelerated early clinical manufacturing
    • Cardiovascular Medical Devices
    • CMS Part D Price Negotiations: Is your drug on the list?
    • COVID-19 navigating global market access
    • Ensuring scientific rigor in external control arms
    • Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
    • Health technology assessment
    • Perspectives from US payers
    • ICER’s impact on payer decision making
    • Making Sense of the Biosimilars Market
    • Medical communications in early phase product development
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Payers Perspectives on Digital Therapeutics
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • Survey results: How to engage healthcare decision-makers
    • The affordability hurdle for gene therapies
    • The Role of ICER as an HTA Organisation
    • Integrating openness and precision for competitive advantage
  • Blog
  • Videos
  • Webinar Channel

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

Related information:

Webpage

Addressing cybersecurity for your medical device

Blog

Post COVID-19 pandemic clinical trial strategies

Webpage

COVID-19 clinical operations

Blog

Not if, but when: Five cybersecurity threats you can expect

Blog

Addressing the inevitable: Managing medical device cybersecurity risks

Media Article

Thwarting Cyber attacks: Steps to implement security into mHealth development

Whitepaper

Reimagining Patient-Centric Clinical Trials with the IoMT

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2025 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?